Dasatinib-Loaded Human Serum Albumin Nanoparticle-Impregnated Hydrogel for Localised Eradication of Residual Melanoma: Integrated In Silico, 3D Spheroid, and Dermatokinetic Evaluation.

Authors

Ganesh Vambhurkar, Paras Famta, Saurabh Shah, Rahul Kumar, Anamika Sharma, Abhishek Sharma, Niharika Puri, Gurpreet Singh, Etikala Amulya, Suraj Wagh, Anupama Sikder, Nitin Pal Kalia, Saurabh Srivastava

Published in

ACS applied bio materials. Volume 9. Issue 16. Pages 7512-7536. Aug 17, 2026.

Abstract

The aim of this study is to investigate active targeting of residual melanoma cells. Melanoma is the most aggressive form of skin cancer for which the conventional therapies often fail to target post-surgical residual cells owing to challenges like chemoresistance, early metastasis, and recurrence. To mitigate the following issues, we repurposed Dasatinib (DAS), an antineoplastic drug approved for chronic myeloid leukaemia, and evaluated its potential in melanoma treatment through a safe, biomacromolecule-based topical delivery system. DAS-loaded human serum albumin nanoparticles (DNPs) were optimised via Box-Behnken design and incorporated into a hydrogel for localised delivery. The DNPs had a particle size of 125.6 ± 1.58 nm with a polydispersity index of 0.242 ± 0.008 and a zeta potential of -14.28 ± 0.22 mV. ATR-FTIR, PXRD, and DSC analyses demonstrated amorphisation of the drug in DNPs devoid of any chemical interactions. The loading and entrapment efficiencies of DAS in DNPs were estimated to be 7.49 ± 0.28 and 89.80 ± 1.52%, respectively. In vitro assays such as the MTT assay, scratch assay, transwell-based invasive assays, cell cycle assay, and 3D tumoroid-based assays demonstrated superior cytotoxic, anti-invasion, and antimigration properties of DNPs. Mechanistic studies demonstrated that DNPs induced apoptosis via caspase-7 upregulation and downregulation of PI3K, p-mTOR, VEGFR, and EGFR. Dermatokinetic analysis of DNPs-entrapped hydrogel confirmed DNPs accumulation in the epidermal and dermal layers near residual melanoma cells, highlighting their therapeutic potential in the management of residual disease.

PMID:
42606056
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.